Table 1 PAX8 immunoreactivity in pancreatic neuroendocrine tumors
Feature | No. of cases | PAX8 immunoreactivity | ||||
|---|---|---|---|---|---|---|
Total no. positive (% of total) | Extent of staining | No. of cases with strong staining intensity (% of pos) | ||||
No. 3+ | No. 2+ | No. 1+ | ||||
Overall | 66 | 49 (74) | 37 | 7 | 5 | 39 (78) |
WHO category | ||||||
1a | 21 | 18 (27) | 14 | 4 | 0 | 15 (83) |
1b | 17 | 12 (18) | 9 | 1 | 2 | 8 (67) |
2 | 28 | 19 (29) | 14 | 2 | 3 | 16 (84) |
Hochwald et al grade | ||||||
Low | 53 | 42 (64) | 31 | 6 | 5 | 34 (81) |
Intermediate | 13 | 7 (10) | 6 | 1 | 0 | 5 (71) |
Location | ||||||
Head | 20 | 14 (21) | 8 | 2 | 4 | 11 (79) |
Body or tail | 46 | 35 (53) | 29 | 5 | 1 | 28 (80) |
Functional clinically | 14 | 11 (17) | 8 | 2 | 1 | |
Insulin producing | 12 | 10 (15) | 8 | 1 | 1 | 8 (80) |
Gastrin producing | 1 | 0 | 0 | 0 | 0 | 0 |
Glucagon producing | 1 | 1 (2) | 0 | 1 | 0 | 1 (100) |
Non-functional | 52 | 38 (58) | 29 | 5 | 4 | 30 (79) |
Metastatic disease | ||||||
Absent | 37 | 29 (44) | 22 | 5 | 2 | 22 |
Present | 29 | 20 (30) | 15 | 2 | 3 | 17 |
Liver | 22 | 16 (24) | 11 | 2 | 3 | 13 |
Lymph node | 20 | 12 (18) | 12 | 0 | 0 | 10 |
Both liver and lymph node | 11 | 6 (9) | 6 | 0 | 0 | 6 |
